ArticleOpen medicine (Warsaw, Poland)2026
Prognostic value of vascular endothelial growth factor subtypes and risk models constructed based on the common pathway of ulcerative colitis and colon cancer.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the mechanism by which triphenyl phosphate promotes malignant phenotypes in bladder and kidney cancer through MMP9 based on bioinformatics analysis and experimental validation.Clinical and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Patients with long-term ulcerative colitis (UC) have a significantly increased risk of colon cancer compared to normal individuals. By analyzing the pathways of ulcerative colitis and colon cancer, we identified a common risk pathway - Vascular Endothelial Growth Factor (VEGF). Methods: Based on the Gene Set Variation Analysis (GSVA) scores of the VEGF pathway in colon cancer patients, we divided them into three groups: high, medium, and low. We performed clinical characteristic and immune-related analyses on these three groups, conducted differential gene analysis, performed univariate and multivariate Cox analyses on the differential genes to screen out gene signatures. A risk model was constructed and validated in the UC cohort. Colon cancer patients were classified into high-and low-risk groups based on risk scores, clinical characteristics, immune microenvironment, immunotherapy, and drug sensitivity were analyzed for both groups. Results: The high expression group had higher clinical staging and pathologic staging, higher immune microenvironment scores, and greater immune cell content. The risk model we constructed demonstrated good prognostic predictive ability not only for colon cancer but also for UC. The high-risk group had a lower survival rate, while the low-risk group had a better response to immunotherapy. Conclusions: These findings provide new insights into the treatment of colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.